This MedLibrary.org supplementary page on Tobramycin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
 |
|
|
Tobramycin
|
|
| Systematic (IUPAC) name | |
| 4-amino-2-[4,6-diamino-3- [3-amino-6-(aminomethyl) -5-hydroxy-tetrahydropyran-2-yl]oxy- 2-hydroxy-cyclohexoxy]-6-(hydroxymethyl) tetrahydropyran-3,5-diol | |
| Identifiers | |
| CAS number | |
| ATC code | J01 S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H37N5O9 |
| Mol. mass | 467.515 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | < 30% |
| Metabolism | ? |
| Half life | Neonates < 1200 g: 11 hrs; > 1200 g 2-9 hrs
Adults: 2-3 hours; longer with impaired renal function |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
D (Injection, Inhalation); B (Ophthalmic) (US) |
| Legal status | |
| Routes | IV, IM, inhalation, ophthalmic |
Tobramycin sulfate is an aminoglycoside antibiotic used to treat various types of bacterial infections, particularly Gram-negative infections.
Mechanism of action
Tobramycin works by binding to a site on the bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, mRNA cannot be translated into protein and cell death ensues. Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa pneumonia due to better lung penetration and bactericidal activity.
Administration
Like all aminoglycosides, tobramycin does not pass the gastro-intestinal tract, so for systemic use it can only be given intravenously or intramuscularly. This formulation for injection is branded Nebcin. Patients with cystic fibrosis will often take an inhalational form (Tobi) for suppression of Pseudomonas aeruginosa infections. Tobramycin is also combined with dexamethasone as an ophthalmic solution (TobraDex).
Bausch & Lomb Pharmaceuticals, Inc. makes a sterile Tobramycin Ophthalmic Solution (eye-drops) with a tobramycin concentration of 0.3%, which is available by prescription only in the United States and Canada. (In some countries, such as Italy, it is available over the counter.) It is mixed with 0.01% benzalkonium chloride as a preservative. These concentrations result in 3 mg per ml and 0.1 mg per ml, respectively.
Side effects
Like other aminoglycosides, tobramycin can cause deafness or a loss of equilibrioception (vertigo) in genetically susceptible individuals. These individuals have a normally harmless mutation in their DNA, that allows the tobramycin to affect their cells. The cells of the ear are particularly sensitive to this.
Tobramycin can also be highly toxic to the kidneys, particularly if multiple doses accumulate over a course of treatment.
For these reasons, when tobramycin is given parenterally, it is usually dosed by body weight. Various formulae exist for calculating tobramycin dosage. Also serum levels of tobramycin are monitored during treatment.
|
||||||||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 13 October 2008, at 15:22.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Tobramycin".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.